William C. Hahn

Broad Institute

Full Professor(heuristic)

Cancer Genomics and Diagnostics · Cancer Research

Compare more Cancer Research professors.

h-index148
i10-index357
Publications1,092
Citations103,065

Grants

15 total · 3 active

NIH #R01CA303334

Context-specific pathway dependencies for nuclear envelope proteins in brain cancer

Active
Amount
$700K–$800K
Period
2026-07-01 → 2031-06-30
PIs
2

Awarded at DANA-FARBER CANCER INST

NIH #R01CA285582

Investigating CREB5-driven mechanisms of immune therapy resistance

Active
Amount
$600K–$700K
Period
2024-12-11 → 2029-12-31
PIs
2

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #U01CA274276

Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity

Active
Amount
$1M–$2M
Period
2022-09-19 → 2027-08-31
PIs
3

Awarded at DANA-FARBER CANCER INST

Active grants are a starting point, not proof of an opening. Confirm recruiting and funding with the professor, current students, and your written offer. Learn how to verify PhD funding →

All Grants

15 total · 3 active

NIH #R01CA303334

Context-specific pathway dependencies for nuclear envelope proteins in brain cancer

Active
Amount
$700K–$800K
Period
2026-07-01 → 2031-06-30
PIs
2

Awarded at DANA-FARBER CANCER INST

NIH #R01CA285582

Investigating CREB5-driven mechanisms of immune therapy resistance

Active
Amount
$600K–$700K
Period
2024-12-11 → 2029-12-31
PIs
2

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #U01CA274276

Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity

Active
Amount
$1M–$2M
Period
2022-09-19 → 2027-08-31
PIs
3

Awarded at DANA-FARBER CANCER INST

NIH #R01CA266642

Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers

Amount
$600K–$700K
Period
2022-05-25 → 2026-04-30
PIs
1

Awarded at BROAD INSTITUTE, INC.

NIH #U01CA250549

Development and implementation of multiplex methods to understand the biology and heterogeneity of patient-derived cancer models

Amount
$1M–$2M
Period
2020-06-15 → 2023-05-31
PIs
1

Awarded at DANA-FARBER CANCER INST

NIH #U01CA176058

The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center

Amount
$1M–$2M
Period
2013-05-01 → 2022-07-31
PIs
1

Awarded at DANA-FARBER CANCER INST

NIH #R03TR003343

Novel genetic dependencies in VRK2 methylated glioblastoma multiforme

Amount
$100K–$200K
Period
2020-09-01 → 2021-08-31
PIs
1

Awarded at DANA-FARBER CANCER INST

NIH #U01CA224146

Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimens

Amount
$1M–$2M
Period
2017-09-30 → 2020-08-31
PIs
1

Awarded at DANA-FARBER CANCER INST

NIH #U01CA199253

Systematic identification of oncogenic KRAS synthetic lethal interactions

Amount
$800K–$900K
Period
2015-09-25 → 2019-08-31
PIs
1

Awarded at BROAD INSTITUTE, INC.

NIH #R01CA130988

Regulation and function of IKKe in breast cancer initiation and maintenance

Amount
$300K–$400K
Period
2009-03-01 → 2019-07-31
PIs
1

Awarded at DANA-FARBER CANCER INST

NIH #P50CA127003

Defining Novel Therapeutic Strategies for KRAS-Mutant CRC

Amount
$200K–$300K
Period
2007-08-31 → 2019-05-31
PIs
1

Awarded at DANA-FARBER CANCER INST

NIH #P01CA154303

Identification of TBK1 inhibitors in KRAS-dependent lung cancer

Amount
$300K–$400K
Period
— → 2017-08-31
PIs
1

Awarded at DANA-FARBER CANCER INST

NIH #P01CA142536

Druggable Genetic Lesions in Pediatric Astrocytoma

Amount
$300K–$400K
Period
— → 2017-01-31
PIs
1

Awarded at DANA-FARBER CANCER INST

NIH #R01AG023145

Regulation and Function of hTERT in Human Cells

Amount
$300K–$400K
Period
2004-08-15 → 2015-03-31
PIs
1

Awarded at DANA-FARBER CANCER INST

NIH #P01CA203655

PROJECT 4: Interrogating PP2A Signaling in Human Cancers

Amount
$300K–$400K
Period
— → —
PIs
1

Awarded at DANA-FARBER CANCER INST

Recent Public Signals

  1. New NIH award: Context-specific pathway dependencies for nuclear envelope proteins in brain cancer2026-07-01
  2. New paper: Table S3 from Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer2026-06-18
  3. New preprint: O-mannosylation and protein maturation check-points represent therapeutic opportunities in BRAF fusion protein oncogenesis2025-08-22

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

Data Freshness

  • Publications as of 2026-07-09
  • Grants as of 2026-08-18

Data may not be current

Find elsewhere

Institution / lab homepage Search on ResearchGate

ORCID: 0000-0003-2840-9791

Professor Insights

Career Trajectory